[Comment] Primary aldosteronism and plasma renin targets

Over the past two decades there have been tremendous advancements in the understanding of both the prevalence and the clinical significance of primary aldosteronism. Where previously only the most extreme cases were likely to be diagnosed and referred for management, primary aldosteronism is now known to be common, though it often remains under-recognised, with a 5–14% prevalence of primary aldosteronism in patients with hypertension who are seen in primary care settings.1 The relative risk of cardiovascular and renal disease in people with primary aldosteronism compared with primary hypertension is well described, and even subclinical primary aldosteronism has been associated with an increased rate of major adverse cardiovascular events.